The role of AXL and the <i>in vitro</i> activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcomaEmmy D.G. Fleuren, Yvonne M.H. Versleijen‐Jonkers|Oncotarget|2014Cited by 47
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor CeritinibAnke van Erp, Yvonne M.H. Versleijen‐Jonkers|Targeted Oncology|2017Cited by 39
Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroupsTess Tomassen, Yvonne M.H. Versleijen‐Jonkers|Immunologic Research|2022Cited by 15